- Total operating performance increased
- Revenue up by 5.7 per cent
- 30 years of dedication to health
The PHOENIX group has presented solid key financial figures for fiscal year 2024/25 despite a volatile market environment. In its 30th anniversary year, the group of companies countered ongoing political and economic challenges with great operational strength. The published results reflect the resilience of the PHOENIX group, which operates throughout Europe.
In fiscal year 2024/25, the group of companies increased its total operating performance by 7.2 per cent compared with the previous year to €61.3 billion. Total operating performance, which comprises revenue and handling for service charge, is the figure relevant to pharmaceutical wholesale. Revenue rose by 5.7 per cent to €49.7 billion, with all regions achieving growth.
Earnings before interest, taxes, depreciation, and amortisation (EBITDA) grew by 20.6 per cent to €1.1 billion. Adjusted for significant one-off effects, EBITDA rose to €1.1 billion, 17.5 per cent higher than in the comparative period. Profit before tax was €465.5 million (previous year: €344.3 million).
Special responsibility towards healthcare in Europe
“Over the past 30 years, the PHOENIX group has transformed itself from a German pharmaceutical wholesaler into Europe’s leading healthcare provider,” explains Sven Seidel, Chief Executive Officer of PHOENIX Pharma SE. “We are aware of the special responsibility that the PHOENIX group has towards healthcare systems in Europe. That is why we are focusing on strengthening our resilience in order to rise above current and future challenges and continue to fulfil our mission: ‘We deliver health.’”
Moderate increase in profit before tax expected
For fiscal year 2025/26, the PHOENIX group anticipates further expansion of its market position in Europe through organic growth and acquisitions, resulting in a slight increase in revenue. The group of companies expects revenue growth in nearly all markets in which it is present. The PHOENIX group expects a moderate increase in profit before tax in the coming fiscal year. A slight increase is expected in the equity ratio.
Key figures of PHOENIX Pharma SE compared with the same period of the previous year
| 2023/24 in €m | 2024/25 in €m | |
| Total operating performance1 | 57,171.8 | 61,288.1 |
| Revenue | 47,064.7 | 49,725.0 |
| EBITDA (before significant one-off effects) | 946.9 | 1,113.0 |
| EBITDA | 933.1 | 1,125.3 |
| EBIT | 498.5 | 608.0 |
| Profit before tax (before significant one-off effects) | 372.0 | 519.5 |
| Profit before tax | 344.3 | 465.5 |
| Profit after tax | 233.2 | 335.5 |
| Equity2 | 3,449.3 | 3,800.3 |
| Equity ratio (in %)2 | 24.1 | 25.2 |
| Net debt2 | 2,853.6 | 2,947.5 |
(Balance sheet date: 31/01/2025)
1 Total operating performance = revenue + handled volume (handling for service charge).
2 As at reporting dates 31/01/2024 and 31/01/2025.
